Sernova Corp

Sernova Corp

September 24, 2007 09:30 ET

FDA Consultant to Help Guide Sernova Through Regulatory Approval Process

KELOWNA, BRITISH COLUMBIA--(Marketwire - Sept. 24, 2007) - Sernova Corp. (TSX VENTURE:SVA) today announced that it has retained the services of Arent Fox LLP to represent Sernova in matters before the US Food and Drug Administration (FDA). Arent Fox partner, James Ravitz, has successfully guided novel cellular therapy products through the FDA regulatory process.

"Cellular therapy is an emerging therapeutic approach and it is important we provide the FDA with the correct preclinical data in our Investigational New Drug application to allow testing of our diabetes therapy, Sertolin, in humans," said Sernova CEO, Justin Leushner. "Mr. Ravitz's and Arent Fox's previous experience and success in this specialized area clearly make them the best choice for strategically advising us toward our regulatory goals."

About Arent Fox

Arent Fox LLP, with offices in Washington, DC, New York and Los Angeles, is a recognized leader in areas including intellectual property, health care, life sciences, and complex litigation. With over 300 lawyers nationwide, Arent Fox has extensive experience in corporate securities, real estate, financial restructuring, bankruptcy, government relations, labor and employment, finance, tax, corporate compliance, and the global business market. The firm represents Fortune 500 companies, government agencies, trade associations, foreign governments, and other entities.

About Sernova

Sernova Corp. is a Canadian-based, health-sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin™ cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information